Determination of thalidomide concentration in human plasma by liquid chromatography‑tandem mass spectrometry

Bai,Nan; Cui,Xiang‑Yong; Wang,Jin; Sun,Chun‑Guang; Mei,He‑Kun; Liang,Bei‑Bei; Cai,Yun; Song,Xiu‑Jie; Gu,Jing‑Kai; Wang,Rui

doi:10.3892/etm.2012.847

February 2013 Volume 5 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February 2013 Volume 5 Issue 2

Full Size Image

Article

Determination of thalidomide concentration in human plasma by liquid chromatography‑tandem mass spectrometry

Authors:
- Nan Bai
- Xiang‑Yong Cui
- Jin Wang
- Chun‑Guang Sun
- He‑Kun Mei
- Bei‑Bei Liang
- Yun Cai
- Xiu‑Jie Song
- Jing‑Kai Gu
- Rui Wang
View Affiliations / Copyright

Affiliations: The Center of Medicine Clinical Research, Chinese PLA General Hospital, Beijing 100853, P.R. China, Research Center for Drug Metabolism, Jilin University, Changchun 130023, P.R. China
Pages: 626-630
|
Published online on: November 30, 2012

https://doi.org/10.3892/etm.2012.847
Expand metrics +

Abstract

A rapid, sensitive and specific analytical method based on high‑performance liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) has been developed for the determination of thalidomide concentration in human plasma. The analyte and internal standard were extracted by liquid‑liquid extraction with ether‑dichloromethane (3:2, v/v) and separated on a TC‑C18 column using methanol‑10 mM ammonium acetate‑formic acid (60:40:0.04, v/v/v) as the mobile phase at a flow rate of 0.9 ml/min. The detection was performed using an API 4000 triple quadrupole mass spectrometer in the positive electrospray ionization (ESI) mode and completed within 3.0 min. The multiple reaction monitoring (MRM) transitions were m/z 259.1→84.0 for the analyte and m/z 195.9→138.9 for temozolomide. The calibration curve exhibited a linear dynamic range of 2‑1500 ng/ml (r>0.9991). The intra‑and inter‑day precisions (as relative standard deviation; RSD) were 6.8‑13.5% and 4.3‑5.0% respectively and the accuracy (as relative error; RE) was 2.0‑3.5%. The recoveries and matrix effects were satisfactory in all the biological matrices examined. This method was successfully used in a pharmacokinetic study of thalidomide in healthy male volunteers receiving an oral administration of a 200‑mg dose.

View Figures

View References

1.	Calabrese L and Resztak K: Thalidomide revisited: pharmacology and clinical applications. Expert Opin Investig Drugs. 7:2043–2060. 1998. View Article : Google Scholar : PubMed/NCBI
2.	Laffitte E and Revuz J: Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf. 3:47–56. 2004. View Article : Google Scholar
3.	Kamikawa R, Ikawa K, Morikawa N, Asaoku H, Iwato K and Sasaki A: The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. Biol Pharm Bull. 29:2331–2334. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Yakoub-Agha I, Attal M, Dumontet C, et al: Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myélome (IFM). Hematol J. 3:185–192. 2002.PubMed/NCBI
5.	Barillé-Nion S, Barlogie B, Bataille R, et al: Advances in biology and therapy of multiple myeloma. Hematology. Am Soc Hematol Educ Program. 248–278. 2003.PubMed/NCBI
6.	Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A and Onel KB: Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr. 145:856–857. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Heine RG, Cameron DJ, Chow CW, Hill DJ and Catto-Smith AG: Esophagitis in distressed infants: poor diagnostic agreement between esophageal pH monitoring and histopathologic findings. J Pediatr. 140:14–19. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Akkoc N, van der Linden S and Khan MA: Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol. 20:539–557. 2006. View Article : Google Scholar : PubMed/NCBI
9.	van der Horst-Bruinsma IE, Clegg DO and Dijkmans BA: Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol. 20(6 Suppl 28): S67–S70. 2002.PubMed/NCBI
10.	Zlnay D, Zlnay M and Rovenský J: Ankylosing spondylitis - the current situation and new therapeutic options. Vnitr Lek. 52:730–735. 2006.(In Slovak).
11.	Mansfield JC, Parkes M, Hawthorne AB, et al: A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease. Aliment Pharmacol Ther. 26:421–430. 2007.PubMed/NCBI
12.	Raza A: Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech. 50:229–235. 2000.
13.	Brocard A, Barbarot S, Milpied B and Stalder JF: Thalidomide in the treatment of chronic discoid lupus erythematosus. Ann Dermatol Venereol. 132:853–856. 2005.(In French).
14.	Bang D: Treatment of Behçet’s disease. Yonsei Med J. 38:401–410. 1997.
15.	Chung F, Lu J, Palmer BD, et al: Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res. 10:5949–5956. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Eriksson T, Björkman S, Fyge A and Ekberg H: Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr. 582:211–216. 1992. View Article : Google Scholar : PubMed/NCBI
17.	Huang YJ, Liao JF and Tsai TH: Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. Biomed Chromatogr. 19:488–493. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Teo SK, Colburn WA and Thomas SD: Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J Clin Pharmacol. 39:1162–1168. 1999.PubMed/NCBI
19.	Saccomanni G, Turini V, Manera C, et al: High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma. J Pharm Biomed Anal. 48:447–451. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Yang X, Hu Z, Chan SY, et al: Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. J Pharm Biomed Anal. 39:299–304. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Chen TL, Vogelsang GB, Petty BG, et al: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos. 17:402–405. 1989.PubMed/NCBI
22.	Zhou S, Li Y, Kestell P and Paxton JW: Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 785:165–173. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Toraño JS, Verbon A and Guchelaar HJ: Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 734:203–210. 1999.
24.	Teo SK, Chandula RS, Harden JL, Stirling DI and Thomas SD: Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 767:145–151. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Teo SK, Harden JL, Burke AB, et al: Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos. 29:1355–1357. 2001.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Determination of thalidomide concentration in human plasma by liquid chromatography‑tandem mass spectrometry

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles